The New York Times reported this week that GlaxoSmithKline, the maker of Avandia, a prescription drug intended for the treatment of Type 2 diabetes, undertook a secret study in 1999 that it has attempted to keep unknown for the past 11 years.

The Los Angeles Times reported that the prescription diabetes drug, Avandia, is linked with an increased risk of hearts attacks, heart failure and strokes, as released in two independent recent study findings.

Bloomberg News has reported that GlaxoSmithKline, the manufacturer of the antidepressant prescription drug Paxil, has entered into settlements with nearly 200 families for a total of $1 billion. The families charged in lawsuits that Paxil caused birth defects.

Confidential government reports disclosed to the New York Times recommend that the diabetes drug Avandia be removed from the market because of the significant risk of heart attacks and the availability of a safer alternative drug.

In January 2010, Leah Mayfield was rushed to the hospital after passing out in the shower. Less than an hour later she was dead. The official cause of death was pulmonary embolism, a blood clot in the lungs. The emergency room physician informed Leah’s mother that that Yaz, a birth control pill prescribed to Leah, could have caused the blood clot.

Facing evidence of increased risks of stroke and heart attack among patients using high doses of certain anti-anemia drugs, the FDA has announced it will ask outside experts to re-examine the safety and proper dosage of Aranesp, Epogen and Procrit

Exposure to certain medical dyes used in MRIs has been linked to the development of the debilitating disease Nephrogenic Systemic Fibrosis

The prescription drug Reglan has been linked to Tardive Dyskinesia (TD), a neurological disorder which can include involuntary spasms and movements.

Lieff Cabraser attorney Wendy Fleishman answers a series of frequently asked questions concerning the birth control drugs Yaz, Yasmin, and Ocella and their side effects.

The FDA still hasn’t restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal